- Home
- RLAY vs REAL Comparison
RLAY vs REAL Comparison
Compare RLAY & REAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- REAL
- Stock Information
- Founded
- RLAY 2015
- REAL 2011
- Country
- RLAY United States
- REAL United States
- Employees
- RLAY N/A
- REAL N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- REAL Other Specialty Stores
- Sector
- RLAY Health Care
- REAL Consumer Discretionary
- Exchange
- RLAY Nasdaq
- REAL Nasdaq
- Market Cap
- RLAY 576.1M
- REAL 641.9M
- IPO Year
- RLAY 2020
- REAL 2019
- Fundamental
- Price
- RLAY $3.63
- REAL $5.31
- Analyst Decision
- RLAY Strong Buy
- REAL Buy
- Analyst Count
- RLAY 11
- REAL 5
- Target Price
- RLAY $18.40
- REAL $8.40
- AVG Volume (30 Days)
- RLAY 1.6M
- REAL 3.0M
- Earning Date
- RLAY 08-05-2025
- REAL 08-05-2025
- Dividend Yield
- RLAY N/A
- REAL N/A
- EPS Growth
- RLAY N/A
- REAL N/A
- EPS
- RLAY N/A
- REAL N/A
- Revenue
- RLAY $7,679,000.00
- REAL $616,717,000.00
- Revenue This Year
- RLAY $14.31
- REAL $11.70
- Revenue Next Year
- RLAY N/A
- REAL $10.10
- P/E Ratio
- RLAY N/A
- REAL N/A
- Revenue Growth
- RLAY N/A
- REAL 11.89
- 52 Week Low
- RLAY $1.78
- REAL $2.24
- 52 Week High
- RLAY $10.72
- REAL $11.38
- Technical
- Relative Strength Index (RSI)
- RLAY 63.22
- REAL 52.98
- Support Level
- RLAY $3.10
- REAL $4.71
- Resistance Level
- RLAY $3.75
- REAL $5.30
- Average True Range (ATR)
- RLAY 0.23
- REAL 0.26
- MACD
- RLAY 0.03
- REAL 0.04
- Stochastic Oscillator
- RLAY 84.42
- REAL 100.00
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About REAL The RealReal Inc.
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.